Biotech | October 27, 2025
Novartis to acquire Avidity Biosciences for $12 billion
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
Launch of Apollo Genomics Institutes would provide genetic counselling, tests, treatment and care for genetic disorders
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
The new wing will cater to all aspects of mother and child health by offering comprehensive, end to end services in radiology, diagnostics, obstetric surgeries and an exclusive gynaecology emergency section
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
